AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00668278 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Measurement of airway pressures
Description: Measurement of peak airway pressure under steady state; measurement of device seal pressure
Study NCT01096355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gamma-secretase/Notch signalling pathway inhibitor RO4929097
Study NCT01096355 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diagnostic laboratory biomarker analysis
Study NCT01096355 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacogenomic studies
Study NCT00528866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bicalutamide
Description: 50 mg (one tablet) daily orally for 6 months, starting within 6 months after registration
Study NCT00528866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: 75 mg/m2 IV over 1 hour on day 1 of each cycle q21 days for 6 cycles, starting 3-6 weeks after completion of radiation therapy
Study NCT00528866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flutamide
Description: 250 mg (two 125-mg capsules) three times daily (total 750 mg) orally for 6 months, starting within 6 months after registration
Study NCT00528866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LHRH agonist
Description: LHRH agonist (such as leuprolide, goserelin, buserelin, or triptorelin) for 6 months, starting within 6 weeks after registration
Study NCT00528866 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy
Study NCT00528866 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: 66.6 Gy (1.8 Gy per fraction, 5 days per week) to the prostate bed (IMRT or 3DCRT), starting 8 weeks after start of hormones
Study NCT02202551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADS-5102
Study NCT02888665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT02888665 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02888665 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT04092972 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Atherectomy
Description: Straub Rotarex S atherectomy and drug-coated balloon DCB. Predilation of the lesion with a predefined ballon (180 sec, Passeo-18). Thus, no direct DCB will be conducted. All DCB lengths (40mm to 200 mm) and Diameters (3mm to 7mm) are eligible for the Trial as long as used in the superficial femoral artery (SFA).
Study NCT04092972 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: POBA and DCB
Description: Standard predilation (POBA) and DCB. Predilation of the lesion with a predefined ballon (180 sec, Passeo-18). Thus, no direct DCB will be conducted. All DCB lengths (40mm to 200 mm) and Diameters (3mm to 7mm) are eligible for the Trial as long as used in the superficial femoral artery (SFA).
Study NCT03607123 — intervention group
Intervention type: OTHER
Intervention: programing of pacemaker
Description: Different programing parameters will be set in different group/stage
Study NCT03607123 — intervention group
Intervention type: PROCEDURE
Intervention: AF ablation
Description: AF ablation can only be performed in Step 3
Study NCT03607123 — intervention group
Intervention type: DRUG
Intervention: Anti arryhthmic drugs
Description: Anti arryhthmic drugs can be prescribed in Step 2, Step3 and SAFE PAF-SND
Study NCT02505581 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Extra dosage - cefuroxime (750mg) I.V
Description: In both groups a second intravenous dose of cefuroxime (750mg) will be administered if the intraoperative time elongates more than three hours or there is an intraoperative bleeding over 1000cc
Study NCT02505581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extra dosage - cefuroxime (750mg) I.V
Description: In both groups a second intravenous dose of cefuroxime (750mg) will be administered if the intraoperative time elongates more than three hours or there is an intraoperative bleeding over 1000cc
Study NCT02505581 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colorectal Surgery
Description: Both groups undergo colorectal surgery. This section does not include rectal surgery ( see Inclusion/exclusion criteria)
Study NCT02505581 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colorectal Surgery
Description: Both groups undergo colorectal surgery. This section does not include rectal surgery ( see Inclusion/exclusion criteria)
Study NCT02505581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 750 mg oral
Description: An oral antibiotic pattern of ciprofloxacin (750 mg / 12h, 2 doses) the day before surgery.
Study NCT02505581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole 250 mg oral
Description: An oral antibiotic pattern of metronidazole (250 / 8h, 3 doses) the day before surgery.
Study NCT02505581 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefuroxime 1.5 g Intravenous
Description: An intravenous antibiotic pattern of cefuroxime 1.5 g during anesthetic induction.
Study NCT02505581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefuroxime 1.5 g Intravenous
Description: An intravenous antibiotic pattern of cefuroxime 1.5 g during anesthetic induction.
Study NCT02505581 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole 1 g Intravenous
Description: An intravenous antibiotic pattern of metronidazole 1 g during anesthetic induction.
Study NCT02505581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole 1 g Intravenous
Description: An intravenous antibiotic pattern of metronidazole 1 g during anesthetic induction.
Study NCT00400309 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: REPEVAX® after REVAXIS®
Description: Tetanus, diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine after tetanus, diphtheria, poliomyelitis (inactivated)
Study NCT00400309 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: REPEVAX® after Placebo
Description: Tetanus, diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine after placebo
Study NCT00881218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regadenoson
Description: Regadenoson 400 micrograms will be administered IV bolus via an antecubital cannula.
Study NCT01499953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Dose: 10 mg Duration: 45 (±5) days Frequency: once daily Application: oral
Study NCT01499953 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fondaparinux
Description: Fondaparinux Dose: 2.5 mg Duration: 45 (±5) days Frequency: once daily Application: subcutaneous
Study NCT01688583 — intervention group
Intervention type: DRUG
Intervention: Fentanyl matrix
Description: Dose will be adjusted in accordance with patient's degree of pain and treatment response in the investigator's judgment.
Study NCT00974090 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo / Teneli (Teneligliptin) + SU (Sulfonylurea)
Description: Placebo for 12 weeks (double-blind period) followed by teneligliptin for an additional 40 weeks (open-label period) in combination with sulfonylurea
Study NCT00974090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teneli / Teneli + SU
Description: Teneligliptin for 12 weeks (double-blind period) followed by teneligliptin for an additional 40 weeks (open-label period) in combination with sulfonylurea
Study NCT00458341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ataluren
Description: Ataluren will be provided as a vanilla-flavored powder to be mixed with water, milk, or apple juice. Participants are to receive a total of 42 doses of ataluren during each cycle, for a total of 84 doses of ataluren in both cycles.
Study NCT01329016 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glyburide
Description: Women with GDM who require treatment will be given glyburide 2.5 mg. Medication will be given at least twice daily and equal doses will be given for each dosing time for the 3 days prior to the pharmacokinetic study day.
Study NCT01329016 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Women with GDM requiring treatment will be given metformin 500 mg. Medication will be administered at least twice daily and equal doses will be given for each dosing time for the 3 days prior to the pharmacokinetic study day.
Study NCT01329016 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glyburide-Metformin combination
Description: Women with GDM requiring treatment will be given glyburide 2.5 mg with metformin 500 mg. Medications will be administered at least twice daily and equal doses will be given for each dosing time 3 days prior to the pharmacokinetic study day.
Study NCT00672061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon or Placebo
Description: Ramelteon 16 mg, tablet, orally, once daily for Periods 1 or 2 and ramelteon placebo-matching tablets, orally, once daily for Periods 1 or 2.
Study NCT00592761 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mendelsohn Maneuver
Description: Mendelsohn Maneuver with Surface Electromyography
Study NCT00866749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Starting Dose 25 mg/m\^2 by vein weekly
Study NCT00866749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Starting Dose 2 mg by vein weekly
Study NCT00866749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-asparaginase
Description: Starting Dose 2000 International units/m2 by vein in week 1
Study NCT00866749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal Methotrexate
Description: Starting Dose 12 mg on week 2 and week 5 injected into spinal fluid
Study NCT00866749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Starting Dose 1g/m2 by vein in weeks 1 and 5
Study NCT00866749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 75 mg/m2 subcutaneous or by vein for four consecutive days on days 1-4 and days 8-11 of both months
Study NCT00866749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Starting Dose 60 mg/m2 by mouth on days 1-14 of each month
Study NCT00866749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Starting Dose at 100 mg/m2 by vein and escalating by 50 mg/m2/dose every 10~+/- 2 days for 5 doses to toxicity (e.g myelosuppression or mucositis grade 3
Study NCT00866749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 25 mg/m2 by vein in weeks 1, 2 and 3
Study NCT00866749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thioguanine
Description: 60 mg/m2 by mouth daily for two weeks
Study NCT03930368 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low GI diet with regular supplementation of raw corn starch
Description: Patients will be guided with a low GI diet with 60%\~70% of energy from carbohydrates. RCS constituted 30%\~50% of daily carbohydrate, and was supplemented as snacks every 4\~6 hours (25g per time) especially at night.
Study NCT02287376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Potassium for Oral Solution
Description: NSAID
Study NCT03877107 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Urinary symptoms profile questionnaire
Description: Validated questionnaire (international) with validated french translation, before and after lumbar puncture, and after surgery if surgery is realized
Study NCT03877107 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Micturition calendar
Description: Micturition calendar on 2 consecutive days, before and after lumbar puncture, and after surgery if surgery is realized
Study NCT02613351 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: scooting
Description: three-wheeled scooter (Monark 662, Monark Exercise AB Sweden) comprised of a single front wheel that provides steering and two rear wheels that create a wide base of support.
Study NCT03659279 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Let's Get Organized
Description: Group intervention aiming to enhance time-management, targeted to persons with mental or neurodevelopment disorders. Each group has 6-8 participants and is lead by two trained group leaders. Goal-directed and other learning strategies are used to train effective time management habits such as maintaining a calendar and wearing a watch. Group sessions are structured with a PowerPoint presentation and a course manual, and information from the group leaders is intermixed with discussion among the participants and tasks to complete.
Study NCT03184324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012
Description: tablet
Study NCT03184324 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: tablet
Study NCT03184324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012 placebo
Description: tablet
Study NCT03184324 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DWP14012 placebo
Description: tablet
Study NCT03184324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole placebo
Description: tablet
Study NCT02234323 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rFVIIIFc
Description: Administered as specified in arm description
Study NCT01550913 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sober Network Interpersonal Psychotherapy (IPT)
Description: IPT will be administered in 16 group 90-minute sessions over 18-20 weeks and 3 individual sessions (at the beginning, middle and end of treatment). These sessions will focus on improving your relationships with others, building sober relationships, setting goals, and increasing coping skills.
Study NCT01550913 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as Usual
Description: Women in the treatment as usual condition will either be referred to appropriate treatment in the community or continue their current substance use treatment.
Study NCT04743479 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: high-resolution MRI/CT examinations
Description: Participants will undergo annual questionnaire survey, laboratory tests and high-resolution MRI/CT examinations of the pancreas. Any suspicious lesions will be further examined by endoscopic ultrasound (EUS).
Study NCT02606461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Selinexor 60mg
Study NCT02606461 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03226405 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Navigation Program
Description: PN program improve access, timeliness and adherence with cancer treatment
Study NCT03226405 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: the standard of care provided by the institution
Study NCT00147290 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantable Cardiac Defibrillator
Description: Implantable cardiac defibrillator with programmable Fast Ventricular tachycardia detection (FVT) window
Study NCT00147290 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantable Cardiac Defibrillator
Description: Implantable cardiac defibrillator with programmable Fast Ventricular tachycardia detection (FVT) window
Study NCT02936063 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical staples
Description: Closure of surgical wound at skin level with surgical staples
Study NCT02936063 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subcuticular sutures
Description: Closure of surgical wound at skin level with subcuticular sutures
Study NCT03457350 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cervical negotiation
Description: trial to bypass severe cervical stenosis
Study NCT02209155 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R-verapamil 75 mg tablet
Study NCT02209155 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03152357 — intervention group
Intervention type: DEVICE
Intervention: ConforMIS iUni, iDuo, or iTotal (CR)
Description: ConforMIS iUni, iDuo, or iTotal (CR)
Study NCT00028821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2-methoxyestradiol
Description: Given orally
Study NCT00028821 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00028821 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01068392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin, Prednisolone
Description: OXALIPLATIN+PREDNISOLONE (OX-P)~D1 Oxaliplatin 130mg/m2 + 5DW 500ml MIV over 2hr~D1-5 Prednisolone 40-30-30 mg/day P.O~every 3 weeks
Study NCT01109173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nepafenac Ophthalmic Suspension, 0.3%
Description: Nepafenac Ophthalmic Suspension, 0.3%, one drop in affected eye once daily, for 16 days. An additional dose was administered between 30-120 minutes prior to surgery.
Study NCT01109173 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nepafenac Ophthalmic Suspension, 0.1%
Description: Nepafenac Ophthalmic Suspension, 0.1%, one drop in affected eye three times daily, for 16 days
Study NCT01109173 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nepafenac Ophthalmic Suspension 0.3% Vehicle
Description: Nepafenac 0.3% vehicle, one drop in affected eye once daily, for 16 days. An additional dose was administered between 30-120 minutes prior to surgery.
Study NCT01109173 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: NEVANAC Vehicle
Description: Nepafenac vehicle, one drop in affected eye three times daily, for 16 days
Study NCT01794364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06291874
Description: PF-06291874 will be administered as an extemporaneously prepared suspension for all doses within the initially planned range of 75 mg to 500 mg.
Study NCT01794364 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Correspondingly, placebo doses will be administered as suspension.
Study NCT03042078 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zero-fluoroscopic ablation
Description: Catheter ablation will be performed under the guidance of Ensite NavX and without the use of fluoroscopy.
Study NCT03042078 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional fluoroscopic ablation
Description: Catheter ablation will be performed under the guidance of Ensite NavX plus fluoroscopy.
Study NCT01729858 — intervention group
Intervention type: DEVICE
Intervention: Ceramic-Ceramic
Description: Zirconia computer aided design and computer milled cores with press on veneers with different thicknesses, gingival embrasure diameters and connector heights.~Fifty percent of the recruited subjects will be given a ceramic-ceramic bridge at baseline.
Study NCT01729858 — intervention group
Intervention type: DEVICE
Intervention: Metal-Ceramic
Description: Metal Ceramic prosthesis with press on veneer with different thicknesses, different diameters of curvature of gingival embrasure and connector heights.~Fifty percent of the recruited subjects will receive the metal-ceramic bridges at baseline.
Study NCT01303965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Start on Day -3 and continue for 1 year
Study NCT01303965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Start on Day -3 and begin tapering on Day +100 until Day +180.
Study NCT01303965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Start between Day +30 and +120 and continue for 1 year.
Study NCT02191020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Total glucosides of paeony & Acitretin Capsules
Study NCT02191020 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acitretin Capsules
Study NCT01049243 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fluocinonide Cream 0.1%
Description: 0.1% Cream, One Application, Twice Daily, 14 Days
Study NCT03279874 — intervention group
Intervention type: OTHER
Intervention: Interviews
Description: Semi-structured one-on-one interviews
Study NCT03943862 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 2Share
Description: The peer-led group program contains of three lessons plus one booster session:~* Lesson 1: Consider the pros and cons of disclosing: Participants reflect on their experience of self-stigma and weigh their pros and cons of (non-)disclosing a suicide attempt.~* Lesson 2: Different ways to disclose: Participants learn about the different ways to disclose and their respective pros and cons. Afterwards participants develop strategies to choose a person to disclose to, and discuss possible responses they might experience.~* Lesson 3: Telling your story: Participants learn how to tell their own story.~* In a booster session, participants will discuss their experiences with disclosure or non-disclosure.